Allena Pharmaceuticals, Inc. (ALNA): Price and Financial Metrics


Allena Pharmaceuticals, Inc. (ALNA)

Today's Latest Price: $1.81 USD

0.36 (-16.59%)

Updated Jan 27 4:00pm

Add ALNA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALNA Stock Price Chart Interactive Chart >

Price chart for ALNA

ALNA Price/Volume Stats

Current price $1.81 52-week high $3.39
Prev. close $2.17 52-week low $0.53
Day low $1.80 Volume 7,782,942
Day high $2.13 Avg. volume 4,505,547
50-day MA $1.41 Dividend yield N/A
200-day MA $1.52 Market Cap 69.31M

Allena Pharmaceuticals, Inc. (ALNA) Company Bio


Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is based in Newton, Massachusetts.


ALNA Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNA Latest Social Stream


Loading social stream, please wait...

View Full ALNA Social Stream

Latest ALNA News From Around the Web

Below are the latest news stories about Allena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNA as an investment opportunity.

Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade

Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

Yahoo | January 12, 2021

Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?

Is (ALNA) Outperforming Other Medical Stocks This Year?

Yahoo | January 12, 2021

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in January

NEWTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in two upcoming investor conferences in January: H.C. Wainwright Bioconnect 2021 Conference * Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a pre-recorded fireside chat, which will become available for on-demand viewing at 6:00 a.m. ET on Monday, January 11, 2021. 15th Annual Stern IR Corporate Access Event * Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will pre-record a corp...

Yahoo | January 4, 2021

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running mana...

Yahoo | December 2, 2020

Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-runni...

Yahoo | December 1, 2020

Read More 'ALNA' Stories Here

ALNA Price Returns

1-mo 33.09%
3-mo 40.31%
6-mo 45.97%
1-year -17.35%
3-year -79.69%
5-year N/A
YTD 41.41%
2020 -53.11%
2019 -49.91%
2018 -45.83%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7188 seconds.